Afatinib (BIBW2992) Dimaleate

• CAT Number: A000112
• CAS Number: 850140-73-7
• Molecular Formula: C24H25ClFN5O3 • 2C4H4O4
• Molecular Weight: 718.08
• Purity: ≥95%
• Target: Protein Tyrosine Kinase/RTK
• Solubility: >35.9mg/mL in DMSO
• Storage: Store at -20°C
• IUPAC Name: (Z)-but-2-enedioic acid;(E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide
• InChI: 1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1
• InChIKey: USNRYVNRPYXCSP-JUGPPOIOSA-N
• SMILES: CN(C/C=C/C(=O)NC1=C(C=C2N=CN=C(C2=C1)NC3=CC(=C(C=C3)F)Cl)O[C@@H]4COCC4)C.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O

Afatinib (BIBW2992) Dimaleate is an irreversible tyrosine kinase inhibitor targeting the ErbB family, including EGFR (HER1) and HER2. It binds covalently to the ATP-binding site, blocking phosphorylation and downstream signaling pathways that drive cell proliferation and survival. Afatinib is approved for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations and is being explored in other cancers involving ErbB overexpression. Its ability to inhibit multiple ErbB receptors makes it a promising option for targeted cancer therapy.